Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 37Terminated 6Unknown 5Withdrawn 2

Sponsor Class

NIH 4FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Breast 1

Conditions

Prostatic Neoplasms 4Breast Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Estramustine × Clear all
NCT00002775 2014-01-06

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
37 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003066 2014-01-06

Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT00003633 2013-12-19

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Unknown
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003717 2013-12-19

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
17 enrolled
Genitourinary

Prostatic Neoplasms

NCT00218205 2005-09-22

A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

Department of Veterans Affairs, New Jersey

Phase 2 Unknown
28 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡